Dr. Hussain on the Implications of the PROfound Trial in mCRPC
In Partnership With:
Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the implications of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).
Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the implications of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).
Findings from the phase III PROfound trial demonstrated that olaparib (Lynparza) improved radiographic progression-free survival (rPFS) versus physician's choice of abiraterone acetate (Zytiga) or enzalutamide (Xtandi) in men with heavily pretreated mCRPC and homologous recombination repair (HRR) gene alterations.
These data, in addition to establishing a new treatment options for patients, provide a robust demonstration of the potential for precision medicine in the field, concludes Hussain.
